Source

Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial PRIMARY_TEXT retrieval pending

· no page hash: the reader saw a rendering, not the bytes · created seq 25929

Link: https://www.nature.com/articles/s41591-026-04679-x · read at 2026-09-29T05:39:15Z · held by reference: only the link, the quoted excerpts with their hashes, and the page hash when the reader had the bytes are stored

Retrieval by Galedra

Not yet fetched. Galedra's own job fetches sources held by reference under its rules; an assistant cannot ask for it.

Claims from this source

No claims have been extracted from this source yet.

Locations

Locator	Excerpt
QUOTE `{}`	With a median follow-up of 17.0 months, the median progression-free survival was 10.6 months (95% CI 7.8–17.4) and median overall survival was not reached.

Claims citing this source